Valneva

Valneva

Biotechnology
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

$548.1M

Market Cap • 10/9/2026

1999

(27 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of France

France

Country

Valuation

P/B

—

P/S

3,3

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

548,1M

EV

649,3M

EV/Revenue

3,9

EV/EBITDA

-6

EV/EBIT

-4,9

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-9,4%

Total Yield

-9,4%

Payout

0%

Retained Earnings

-248,8M

Profitability

Gross Margin

16,4%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

58,4%

Capex/Revenue

1,6%

Capex/D&A

11,2%

Capex/OCF

-4,2%

SBC/OCF

—

% PPE

33,1%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

3,8%

CAGR Op. Income 5Y

-1,6%

CAGR Net Income 5Y

3,8%

CAGR EPS 5Y

-5,9%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

2,2

Quick Ratio

1,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium